Abstract:Selective inhibition of alpha-helix-mediated protein-protein interactions (PPIs) with small organic molecules provides great potential for the discovery of chemical probes and therapeutic agents. Protein Data Bank data mining using the HippDB database indicated that (1) the side chains of hydrophobic projecting hot spots at positions i, i + 3, and i + 7 of an alpha-helix had few orientations when interacting with the second protein and (2) the hot spot pockets of PPI complexes had different sizes, shapes, and chemical groups when interacting with the same hydrophobic projecting hot spots of alpha-helix. On the basis of these observations, a small organic molecule, 4'-fluoro-N-phenyl-[1,1'-biphenyl]-3-carboxamide, was designed as a generic scaffold that itself directly mimics the binding mode of the side chains of hydrophobic projecting hot spots at positions i, i + 3, and i + 7 of an alpha-helix. Convenient decoration of this generic scaffold led to the selective disruption of alpha-helix-mediated PPIs. A series of small-molecule inhibitors selective for beta-catenin/B-cell lymphoma 9 (BCL9) over beta-catenin/cadherin PPIs was designed and synthesized. The binding mode of new inhibitors was characterized by site-directed mutagenesis and structure-activity relationship studies. This new class of inhibitors can selectively disrupt beta-catenin/BCL9 over beta-catenin/cadherin PPIs, suppress the transactivation of canonical Wnt signaling, downregulate the expression of Wnt target genes, and inhibit the growth of Wnt/beta-catenin-dependent cancer cells.

Structure‐Based Design of Bicyclic Helical Peptides That Target the Oncogene β‐Catenin

Development of Structure-Based Pharmacophore to Target the Β-Catenin-tcf Protein–protein Interaction

Optimization of Peptidomimetics as Selective Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction.

Rational design of selective small-molecule inhibitors for β-catenin/B-cell lymphoma 9 protein-protein interactions.

Structure-based discovery of a novel inhibitor targeting the β-catenin/Tcf4 interaction.

Rational Design of Small-Molecule Inhibitors for Β-Catenin/t-cell Factor Protein–Protein Interactions by Bioisostere Replacement

Discovery of small molecule modulators targeting β-catenin interactions using molecular docking and molecular dynamics strategy

A novel peptide stapling strategy enables the retention of ring-closing amino acid side chains for the Wnt/β-catenin signalling pathway

Cyanobacterial peptides as a prototype for the design of cathepsin D inhibitors.

Design, synthesis, biological activity and structural analysis of cyclic peptide inhibitors targeting the substrate recruitment site of cyclin-dependent kinase complexes

Discovery of Selective Small-Molecule Inhibitors for the β-Catenin/T-Cell Factor Protein-Protein Interaction through the Optimization of the Acyl Hydrazone Moiety.

Structure Based Design of Bicyclic Peptide Inhibitors of RbAp48

Structure-Based Optimization of Small-Molecule Inhibitors for the Β-Catenin/b-cell Lymphoma 9 Protein-Protein Interaction.

Medicinal Chemistry Strategies for the Development of Inhibitors Disrupting β-Catenin's Interactions with Its Nuclear Partners

Computational Design of Novel Cyclic Peptides Endowed with Autophagy-Inhibiting Activity on Cancer Cell Lines

A Protac Peptide Induces Durable Beta-Catenin Degradation And Suppresses Wnt-Dependent Intestinal Cancer

Design of cyclic peptides as novel inhibitors of ICOS/ICOSL interaction

Direct Targeting of -Catenin in the Wnt Signaling Pathway: Current Progress and Perspectives

Biomimetic and Self-Assembled Nanoclusters Targeting Β-Catenin for Potent Anticancer Therapy and Enhanced Immunotherapy.

Antibody–peptide conjugates deliver covalent inhibitors blocking oncogenic cathepsins

Molecular docking-aided identification of small molecule inhibitors targeting β-catenin-TCF4 interaction